Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reaffirmed a buy rating and set a $75.00 price objective on shares of Emergent Biosolutions in a report on Sunday, April 21st. Citigroup raised Atara Biotherapeutics from a sell rating to a neutral rating and upped their price objective for the stock from $23.00 to $24.00 in a report on Monday, June 3rd. Zacks Investment Research raised HB Fuller from a sell rating to a hold rating in a report on Tuesday, June 11th. Morgan Stanley set a $207.00 price target on Alibaba Group and gave the company a buy rating in a research note on Friday, July 12th. Finally, Goldman Sachs Group raised Puxin from a neutral rating to a buy rating and increased their price target for the company from $51.00 to $56.00 in a research note on Friday, May 3rd. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Cigna presently has an average rating of Buy and a consensus price target of $217.40.
NYSE:CI opened at $173.69 on Wednesday. The stock’s fifty day moving average price is $161.76. Cigna has a 52-week low of $141.95 and a 52-week high of $226.60. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.70 and a current ratio of 0.70. The firm has a market cap of $65.91 billion, a P/E ratio of 12.21, a price-to-earnings-growth ratio of 0.88 and a beta of 0.71.
Several hedge funds have recently bought and sold shares of the company. Clarfeld Financial Advisors LLC bought a new stake in shares of Cigna in the 4th quarter valued at $25,000. Lowe Wealth Advisors LLC bought a new stake in shares of Cigna in the 1st quarter valued at $34,000. Truvestments Capital LLC bought a new stake in shares of Cigna in the 1st quarter valued at $37,000. Lavaca Capital LLC bought a new stake in shares of Cigna in the 1st quarter valued at $40,000. Finally, C J Advisory Inc bought a new stake in shares of Cigna in the 1st quarter valued at $40,000. 88.08% of the stock is currently owned by institutional investors.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.